142 related articles for article (PubMed ID: 9367020)
1. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.
Montgomery RC; Hoffman JP; Riley LB; Rogatko A; Ridge JA; Eisenberg BL
Ann Surg Oncol; 1997; 4(7):551-6. PubMed ID: 9367020
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
3. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
[TBL] [Abstract][Full Text] [Related]
4. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
5. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy.
Katz A; Hanlon A; Lanciano R; Hoffman J; Coia L
Int J Radiat Oncol Biol Phys; 1998 May; 41(2):393-6. PubMed ID: 9607356
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of CA-19-9 in pancreatic carcinoma.
Nakao A; Oshima K; Nomoto S; Takeda S; Kaneko T; Ichihara T; Kurokawa T; Nonami T; Takagi H
Semin Surg Oncol; 1998; 15(1):15-22. PubMed ID: 9671952
[TBL] [Abstract][Full Text] [Related]
8. Biliary CA 19-9 values correlate with the risk of hepatic metastases in patients with adenocarcinoma of the pancreas.
Montgomery RC; Hoffma JP; Ross EA; Riley LB; Ridge JA; Eisenberg BL
J Gastrointest Surg; 1998; 2(1):28-35. PubMed ID: 9841965
[TBL] [Abstract][Full Text] [Related]
9. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of CA 19-9 serum course in pancreatic cancer.
Safi F; Schlosser W; Falkenreck S; Beger HG
Hepatogastroenterology; 1998; 45(19):253-9. PubMed ID: 9496523
[TBL] [Abstract][Full Text] [Related]
11. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
[TBL] [Abstract][Full Text] [Related]
12. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
13. Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.
Piagnerelli R; Marrelli D; Roviello G; Ferrara F; Di Mare G; Voglino C; Petrioli R; Marini M; Macchiarelli R; Roviello F
Tumour Biol; 2016 Feb; 37(2):1959-66. PubMed ID: 26334620
[TBL] [Abstract][Full Text] [Related]
14. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
[TBL] [Abstract][Full Text] [Related]
16. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms.
Safi F; Schlosser W; Kolb G; Beger HG
J Gastrointest Surg; 1997; 1(2):106-12. PubMed ID: 9834336
[TBL] [Abstract][Full Text] [Related]
18. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.
Motoi F; Murakami Y; Okada KI; Matsumoto I; Uemura K; Satoi S; Sho M; Honda G; Fukumoto T; Yanagimoto H; Kinoshita S; Kurata M; Aoki S; Mizuma M; Yamaue H; Unno M;
World J Surg; 2019 Feb; 43(2):634-641. PubMed ID: 30298281
[TBL] [Abstract][Full Text] [Related]
19. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
